Sagimet Biosciences Inc.
SGMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001400118
In the last 90 days, Sagimet Biosciences Inc. insiders filed 0 open-market purchases and 5 sales; 122 institutions reported holding it in 13F filings for Q2 2026, worth $394.3M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Sagimet Biosciences Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 3 insiders, $4.51M in total
- Insiders trading
- 3
- Net value
- −$4.51M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Sagimet Biosciences Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kemble George | Director | 62,161 | Aug 17, 2026 | 5 |
| Happel David | President & CEO | 741,570 | Jul 22, 2026 | 4 |
| Rozek Elizabeth | Chief Legal & Admin. Officer | 224,414 | Jul 22, 2026 | 5 |
| Seidenberg Beth C | Director | 46,875Indirect | Jun 15, 2026 | 1 |
| Grammer Elizabeth A | Director | – | Jun 15, 2026 | 1 |
| Hoelscher Paul W. | Director | – | Jun 15, 2026 | 1 |
| Phillips Anne M. | Director | – | Jun 15, 2026 | 1 |
| Jarrett Jennifer | Director | – | Jun 15, 2026 | 1 |
| Grauer Andreas | Chief Medical Officer | – | Jun 1, 2026 | 2 |
| Chauche Thierry | Chief Financial Officer | 59,688 | Jun 1, 2026 | 3 |
| Martins Eduardo Bruno | Chief Medical Officer | 147,296 | Feb 20, 2026 | 2 |
| Walbert Timothy P | Director | – | Jun 10, 2025 | 0 |
| Parsey Merdad | Director | 12,794 | Jun 7, 2024 | 0 |
| NEA 13 GP, Ltd | 10% Owner | 0 | Jan 31, 2024 | 0 |
| NEA Partners 13, Limited Partnership | 10% Owner | 0 | Jan 31, 2024 | 0 |
| Kerins Patrick J | 10% Owner | 13,139 | Jan 31, 2024 | 0 |
| Sandell Scott D | 10% Owner | 6,997Indirect | Jan 31, 2024 | 0 |
| Baskett Forest | 10% Owner | 11,300Indirect | Jan 31, 2024 | 0 |
| New Enterprise Associates 13 LP | 10% Owner | 3,000,275 | Jan 31, 2024 | 0 |
| KPCB Pandemic & Bio Defense Fund LLC | 10% Owner | 1,899,475Indirect | Jul 20, 2023 | 0 |
| KPCB PBD Associates, LLC | 10% Owner | 1,899,475Indirect | Jul 20, 2023 | 0 |
| Rodgers Richard J | Director | – | Jul 20, 2023 | 0 |
| Hom Dennis | Chief Financial Officer | – | Jul 20, 2023 | 0 |
| Rimac Anthony M | Chief Operating Officer | – | Jul 20, 2023 | 0 |
| Wu Jinzi Jason | Director | 1,654,701Indirect | Jul 20, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 (view filing)4:05 PM ET | Aug 14 | 3 days | Kemble GeorgeDirector | SSaleSeries A Common Stock | −351.0K | $10.23 | −$3.59M | −85.0%62.2K after | 10b5-1 |
| Aug 12, 2026 (view filing)7:41 PM ET | Aug 11 | 1 day | Kemble GeorgeDirector | SSaleSeries A Common Stock | −20.2K | $9.95 | −$201.1K | −24.5%62.2K after | 10b5-1 |
| Jul 22, 2026 (view filing)4:05 PM ET | Jul 20 | 2 days | Happel DavidPresident & CEO | SSaleSeries A Common Stock | −64.1K | $7.76 | −$497.1K | −8.0%741.6K after | |
| Jul 22, 2026 (view filing)4:05 PM ET | Jul 20 | 2 days | Rozek ElizabethChief Legal & Admin. Officer | SSaleSeries A Common Stock | −10.5K | $7.76 | −$81.8K | −4.5%224.4K after | |
| Jul 22, 2026 (view filing)4:05 PM ET | Jul 20 | 2 days | Kemble GeorgeDirector | SSaleSeries A Common Stock | −18.8K | $7.46 | −$140.5K | −23.3%62.2K after | 10b5-1 |
| Feb 12, 2026 (view filing) | Feb 10 | 2 days | Happel DavidPresident & CEO | SSaleSeries A Common Stock | −12.1K | $5.36 | −$64.9K | −1.8%677.6K after | |
| Feb 12, 2026 (view filing) | Feb 10 | 2 days | Chauche ThierryChief Financial Officer | SSaleSeries A Common Stock | −1.31K | $5.36 | −$7.03K | −7.7%15.7K after | |
| Feb 12, 2026 (view filing) | Feb 10 | 2 days | Martins Eduardo BrunoChief Medical Officer | SSaleSeries A Common Stock | −3.64K | $5.36 | −$19.5K | −3.4%103.3K after | |
| Feb 12, 2026 (view filing) | Feb 10 | 2 days | Rozek ElizabethChief Legal & Admin. Officer | SSaleSeries A Common Stock | −2.62K | $5.36 | −$14.1K | −1.4%191.0K after | |
| Nov 21, 2025 (view filing) | Nov 20 | 1 day | Kemble GeorgeExecutive Chairman | SSaleSeries A Common Stock | −37.7K | $7.69 | −$289.8K | −31.8%81.0K after | 10b5-1 |
| Jul 23, 2025 (view filing) | Jul 21 | 2 days | Happel DavidPresident & CEO | SSaleSeries A Common Stock | −65.5K | $9.13 | −$597.8K | −8.7%689.7K after | |
| Jul 23, 2025 (view filing) | Jul 21 | 2 days | Martins Eduardo BrunoChief Medical Officer | SSaleSeries A Common Stock | −8.28K | $9.13 | −$75.6K | −7.2%106.9K after | |
| Jul 23, 2025 (view filing) | Jul 21 | 2 days | Rozek ElizabethGeneral Counsel and CCO | SSaleSeries A Common Stock | −10.8K | $9.13 | −$98.4K | −5.5%183.7K after | |
| Jul 25, 2024 (view filing) | Jul 23 | 2 days | Kemble GeorgeExecutive Chairman | SSaleSeries A Common Stock | −23.6K | $3.17 | −$74.9K | −16.6%118.7K after | 10b5-1 |
| Jul 23, 2024 (view filing) | Jul 19 | 4 days | Martins Eduardo BrunoChief Medical Officer | SSaleSeries A Common Stock | −8.36K | $3.10 | −$25.9K | −9.3%81.2K after | |
| Jul 23, 2024 (view filing) | Jul 19 | 4 days | Rozek ElizabethGeneral Counsel and CCO | SSaleSeries A Common Stock | −10.9K | $3.10 | −$33.8K | −6.4%160.5K after | |
| Jul 23, 2024 (view filing) | Jul 19 | 4 days | Kemble GeorgeExecutive Chairman | SSaleSeries A Common Stock | −14.1K | $3.10 | −$43.6K | −9.0%142.3K after | |
| Mar 28, 2024 (view filing) | Mar 26 | 2 days | Happel DavidPresident & CEO | PPurchaseSeries A Common Stock | +12.1K | $5.27 | +$63.8K | +1.9%639.2K after | |
| Dec 8, 2023 (view filing) | Dec 7 | 1 day | Happel DavidPresident & CEO | PPurchaseSeries A Common Stock | +1.60K | $4.10 | +$6.56K | +0.3%627.1K after | |
| Nov 20, 2023 (view filing) | Nov 16 | 4 days | Happel DavidPresident & CEO | PPurchaseSeries A Common Stock | +590 | $2.35 | +$1.39K | New position590 after | |
| Jul 20, 2023 (view filing)6:56 PM ET | Jul 18 | 2 days | Kerins Patrick J and 5 others10% Owner | SSaleSeries A Common Stock | −662 | $16.00 | −$10.6K | 0.0%3.82M after | |
| Jul 20, 2023 (view filing)6:56 PM ET | Jul 18 | 2 days | Kerins Patrick J and 5 others10% Owner | PPurchaseSeries A Common Stock | +30.0K | $16.00 | +$480.0K | +0.8%3.85M after | |
| Jul 20, 2023 (view filing) | Jul 18 | 2 days | Seidenberg Beth CDirector | PPurchaseSeries A Common Stock | +46.9K | $16.00 | +$750.0K | New position46.9K after |